Real-World Anti-VEGF Data Disappointing
The reality of antivascular endothelial growth factor (anti-VEGF) treatments for neovascular age-related macular degeneration seen in US ophthalmology practices falls far short of the promise of clinical trial results, according to the results of a new analysis.
"In the real world, patients do poorly," Thomas Ciulla, MD, told Medscape Medical News. "It's very concerning. There has to be a better way to address the ocular healthcare of these patients."
The analysis of 750,000 patients is the first large study in the United States of anti-VEGF results outside of randomized, controlled clinical trials, and it echoes the findings from similar European studies, he said.
Dr Ciulla, from the Indiana School of Medicine in Indianapolis and an employee of Ophthotech Corporation, presented the results here at the American Society of Retina Specialists (ASRS) 2016 Annual Meeting.
Second Quarter 2016 Revenue to be in the range of $9.3 million to $9.5 million, an increase of over 50% versus First Quarter 2016
Second Quarter 2016 U.S. Revenue to be in the range of $7.0 million to $7.2 million, an increase of over 65% versus the First Quarter of 2016
Company modifies its liquidity and revenue covenants under its loan facility
Company to report Second Quarter 2016 Financial Results on August 4, 2016
ATLANTA, July 26, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today pre-announced its revenue for the second quarter of 2016 and also announced certain modifications to its loan facility.
Second quarter 2016 revenue is expected to be in the range of $9.3 million to $9.5 million, representing sequential growth of more than 50% over the first quarter of 2016 and growth in excess of 50% over the second quarter of 2015. Second quarter 2016 U.S. revenue is expected to be in the range of $7.0 million to $7.2 million, representing sequential growth of more than 65% over the first quarter of 2016 and growth in excess of 75% over the second quarter of 2015.
"We are delighted to announce record sales of ILUVIEN in the second quarter of 2016. I am pleased with the level of execution by our management team and the performance by our sales force. They have worked tirelessly to improve ILUVIEN education and adoption," said Dan Myers, Chief Executive Officer of Alimera Sciences. "While we performed well during this quarter, we believe we are still early in the adoption of ILUVIEN and that an opportunity for significant growth and market penetration clearly remains."
The Company also announced that it has modified the liquidity and revenue covenants in its existing loan agreement with Hercules Capital, Inc. The modification allows for the reduction of Alimera's liquidity threshold and reduces its trailing three-month revenue requirement through the period ending August 31, 2016. Additional terms of the loan agreement, as modified, are disclosed in the Company's Current Report on Form 8-K filed today in conjunction with this press release.
"We expect our refinancing plans will provide additional liquidity and improved financial flexibility during this period of growth and we believe this modification affords us additional time to accomplish our refinancing plans," said Rick Eiswirth, President and Chief Financial Officer of Alimera Sciences.
Hello gang it's been a while since I have posted. The recent news has been great, I guess good things come to those who wait. We just need the volume to increase, that will be our indication that the secret is really out. Psivida has many good things in the pipeline. Growing slow and steady. I would really love to hear how Roche and Genetech feel a about the preclinical trial of Avastin and Tethadur. This really is a major step into the future of drug delivery.